A BILL 
To amend title XVIII of the Social Security Act to establish 
under the Medicare prescription drug program a min-
imum amount of price concessions for insulin to be 
passed through to beneficiaries at the point-of-sale, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Insulin Savings for 
4
Patients Act’’. 
5
05:35 Feb 24, 2022
H6757
2 
•HR 6757 IH
SEC. 2. NEGOTIATED PRICE CONCESSIONS FOR INSULIN AT 
1
2
CARE PROGRAM. 
3
(a) IN GENERAL.—Section 1860D–2(d)(1) of the So-
4
cial Security Act (42 U.S.C. 1395w–102(d)(1)) is amend-
5
ed— 
6
(1) in subparagraph (A), by striking ‘‘Under’’ 
7
and inserting ‘‘Subject to subparagraph (D), 
8
under’’; and 
9
(2) by adding at the end the following new sub-
10
paragraph: 
11
‘‘(D) NEGOTIATED
PRICE
CONCESSIONS 
12
FOR INSULIN AT POINT-OF-SALE.— 
13
‘‘(i) IN
GENERAL.—For drugs dis-
14
pensed in plan year 2022 or a subsequent 
15
plan year, the minimum percentage de-
16
scribed in clause (ii) for such plan year of 
17
price concessions negotiated between man-
18
ufacturers and a prescription drug plan or 
19
MA–PD plan (or any entity that provides 
20
pharmacy benefits management services 
21
under a contract with any such prescrip-
22
tion drug plan or MA–PD plan) and taken 
23
into account under subparagraph (B) in 
24
determining negotiated prices for the plan 
25
year for covered part D drugs that are in-
26
05:35 Feb 24, 2022
H6757
3 
•HR 6757 IH
sulin provided under such a plan shall be 
1
provided to enrollees of such a plan at 
2
pharmacies or by mail order service at the 
3
point-of-sale of such drugs. 
4
‘‘(ii) AMOUNT
OF
PRICE
CONCES-
5
SION.—For purposes of clause (i), and 
6
subject to clause (iii), the minimum per-
7
centage described in this clause is— 
8
‘‘(I) for drugs dispensed in plan 
9
year 2022, 50 percent; 
10
‘‘(II) for drugs dispensed in plan 
11
year 2023, 75 percent; and 
12
‘‘(III) for drugs dispensed in 
13
plan year 2024 or a subsequent plan 
14
year, 100 percent. 
15
‘‘(iii) MODIFICATION
OF
MINIMUM 
16
PERCENTAGE.—For plan years beginning 
17
on or after January 1, 2024, the Secretary 
18
may, through notice and comment rule-
19
making, specify a percentage other than 
20
the percentage described in clause (ii) for 
21
a plan year, except that in specifying such 
22
percentage the Secretary shall not specify 
23
a percentage that is less than 50 percent 
24
of the negotiated price concession for such 
25
05:35 Feb 24, 2022
H6757
4 
•HR 6757 IH
plan year. Any percentage specified pursu-
1
ant to the authority of the previous sen-
2
tence for a plan year that would be less 
3
than the percentage otherwise described in 
4
clause (ii) for the plan year may only be 
5
applied if such reduction in percentage is 
6
justified as a benefit to individuals enrolled 
7
under this title.’’. 
8
(b) INCLUSION OF INFORMATION IN BID SUBMIS-
9
SION.—Section 1860D–11(b)(2) of the Social Security Act 
10
(42 U.S.C. 1395w–11(b)(2)) is amended— 
11
(1) by redesignating subparagraph (F) as sub-
12
paragraph (G); and 
13
(2) by inserting after subparagraph (E) the fol-
14
lowing new subparagraph: 
15
‘‘(F) POINT-OF-SALE PRICE CONCESSIONS 
16
FOR INSULIN.—For plan years beginning on or 
17
after January 1, 2022, an estimate of the ag-
18
gregate price concessions for all insulin nego-
19
tiated by the plan for such plan year.’’. 
20
(c) GAO STUDY AND REPORT ON INSULIN PRIC-
21
ING.—Not later than 2 years after the date of the enact-
22
ment of this Act, and annually thereafter, the Comptroller 
23
General of the United States shall— 
24
05:35 Feb 24, 2022
H6757
5 
•HR 6757 IH
(1) conduct a study on the effects of the imple-
1
mentation of the requirement described in subpara-
2
graph (D) of section 1860D–2(d)(1) of the Social 
3
Security Act (42 U.S.C. 1395w–102(d)(1)), as 
4
added by subsection (a), including an analysis of— 
5
(A) trends in the list and net prices of in-
6
sulin for qualified prescription drug coverage 
7
offered by a prescription drug plan under part 
8
D of the Social Security Act or an MA–PD 
9
plan under part C of such title; 
10
(B) savings on insulin for individuals en-
11
rolled in a prescription drug plan under part D 
12
of the Social Security Act or an MA–PD plan 
13
under part C of such title; 
14
(C) trends in out-of-pocket costs for indi-
15
viduals enrolled in such plans, as compared to 
16
individuals enrolled in a group health plan (as 
17
defined in section 2791(a) of the Public Health 
18
Service Act (42 U.S.C. 300gg–91(a)), a State 
19
plan under title XIX of the Social Security Act, 
20
or a qualified health plan offered through an 
21
Exchange established under title I of the Pa-
22
tient Protection and Affordable Care Act (42 
23
U.S.C. 18001 et seq.); and 
24
05:35 Feb 24, 2022
H6757
6 
•HR 6757 IH
(D) approval and market entry of bio-
1
similar insulin under section 351(k) of the Pub-
2
lic Health Service Act (42 U.S.C. 262); and 
3
(2) submit to the Committee on Energy and 
4
Commerce and the Committee on Ways and Means 
5
in the House of Representatives, and the Committee 
6
on Finance in the Senate, a report on the study con-
7
ducted under paragraph (1), with recommendations 
8
on how to enhance the access of individuals enrolled 
9
in a prescription drug plan under part D of the So-
10
cial Security Act or an MA–PD plan under part C 
11
of such title to lower out-of-pocket costs for insulin. 
12
(d) TRANSPARENCY.—Section 1860D–1(c)(3) of the 
13
Social Security Act (42 U.S.C. 1395w–101(c)(3)) is 
14
amended by adding at the end the following new subpara-
15
graph: 
16
‘‘(C) 
ADDITIONAL
INFORMATION.—For 
17
plan year 2022 and each subsequent plan year, 
18
such information referred to in paragraph 
19
(2)(A) shall also include, for a plan year, infor-
20
mation regarding the requirement described in 
21
subparagraph (D) of section 1860D–2(d)(1) 
22
with respect to insulin negotiated by the plan 
23
for such plan year.’’. 
24
Æ 
05:35 Feb 24, 2022
H6757
